(Q38599011)

4 September 2017

title

Hit and lead criteria in drug discovery for infectious diseases of the developing world (English)

1 reference

Rob Hooft van Huijsduijnen

4 September 2017

1 reference

4

0 references

Kiyoshi Kita

6

0 references

Charles E Mowbray

object named as

Charles E Mowbray

7

0 references

Jeremy Burrows

2

object named as

Jeremy N Burrows

1 reference

4 September 2017

Kei Katsuno

1

1 reference

4 September 2017

Ken Duncan

3

1 reference

4 September 2017

Takushi Kaneko

5

1 reference

4 September 2017

Dennis Schmatz

8

1 reference

4 September 2017

Peter Warner

9

1 reference

4 September 2017

B T Slingsby

10

1 reference

4 September 2017

publication date

5 October 2015

1 reference

Nature Reviews Drug Discovery

4 September 2017

published in

1 reference

4 September 2017

volume

14

1 reference

4 September 2017

issue

11

1 reference

4 September 2017

page(s)

751-758

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd4683

4 September 2017

exact match

0 references

cites work

Drug discovery in pharmaceutical industry: productivity challenges and trends

1 reference

Innovative lead discovery strategies for tropical diseases

31 March 2020

1 reference

Advancing drug innovation for neglected diseases-criteria for lead progression

31 March 2020

1 reference

Designing the next generation of medicines for malaria control and eradication

31 March 2020

1 reference

Phenotypic vs. target-based drug discovery for first-in-class medicines

31 March 2020

1 reference

The discovery of first-in-class drugs: origins and evolution.

31 March 2020

1 reference

Drugs for bad bugs: confronting the challenges of antibacterial discovery

31 March 2020

1 reference

Fluorine Modulates Species Selectivity in the Triazolopyrimidine Class of Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors

31 March 2020

1 reference

Cultivation of plasmodium spp.

31 March 2020

1 reference

Apoptosis stalks Plasmodium falciparum maintained in continuous culture condition

31 March 2020

1 reference

Chagas disease drug discovery: toward a new era.

31 March 2020

1 reference

Malaria medicines: a glass half full?

31 March 2020

1 reference

A major transition in malaria treatment: the adoption and deployment of artemisinin-based combination therapies.

31 March 2020

1 reference

New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline

31 March 2020

1 reference

Delamanid: A new armor in combating drug-resistant tuberculosis

31 March 2020

1 reference

Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits

31 March 2020

1 reference

A molecular marker of artemisinin-resistant Plasmodium falciparum malaria

31 March 2020

1 reference

Spread of artemisinin resistance in Plasmodium falciparum malaria

31 March 2020

1 reference

Microbiology: Malaria runs rings round artemisinin

31 March 2020

1 reference

A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria

31 March 2020

1 reference

Thousands of chemical starting points for antimalarial lead identification

31 March 2020

1 reference

Chemical genetics of Plasmodium falciparum

31 March 2020

1 reference

In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen

31 March 2020

1 reference

Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery

31 March 2020

1 reference

A murine model of falciparum-malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytes

31 March 2020

1 reference

Quinolone-3-diarylethers: a new class of antimalarial drug.

31 March 2020

1 reference

Drug resistance genomics of the antimalarial drug artemisinin

31 March 2020

1 reference

Novel mutations in K13 propeller gene of artemisinin-resistant Plasmodium falciparum

31 March 2020

1 reference

Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker

31 March 2020

1 reference

Towards an in vitro model of Plasmodium hypnozoites suitable for drug discovery

31 March 2020

1 reference

The biology of sexual development of Plasmodium: the design and implementation of transmission-blocking strategies

31 March 2020

1 reference

Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis

31 March 2020

1 reference

A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis

31 March 2020

1 reference

Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents

31 March 2020

1 reference

Microbial phenotypic heterogeneity and antibiotic tolerance.

31 March 2020

1 reference

The search for new sterilizing anti-tuberculosis drugs

31 March 2020

1 reference

Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis

31 March 2020

1 reference

High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis.

31 March 2020

1 reference

Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.

31 March 2020

1 reference

Foamy macrophages and the progression of the human tuberculosis granuloma

31 March 2020

1 reference

Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions

31 March 2020

1 reference

Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery

31 March 2020

1 reference

New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics

31 March 2020

1 reference

Treatment of visceral leishmaniasis

31 March 2020

1 reference

An update on pharmacotherapy for leishmaniasis

31 March 2020

1 reference

Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.

31 March 2020

1 reference

Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay

31 March 2020

1 reference

Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi.

31 March 2020

1 reference

New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource.

31 March 2020

1 reference

Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections

31 March 2020

1 reference

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

31 March 2020

1 reference

Drug discovery for neglected diseases: molecular target-based and phenotypic approaches

31 March 2020

1 reference

Malaria and artemisinin derivatives: an updated review

31 March 2020

1 reference

Embryotoxicity of the artemisinin antimalarials and potential consequences for use in women in the first trimester

31 March 2020

1 reference

Safety of artemisinin antimalarials

31 March 2020

1 reference

R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation

31 March 2020

1 reference

Camptothecin and taxol: historic achievements in natural products research.

31 March 2020

1 reference

Targeting mammalian target of rapamycin (mTOR) for health and diseases.

31 March 2020

1 reference

The Global Health Innovative Technology (GHIT) Fund: financing medical innovations for neglected populations

31 March 2020

1 reference

The GHIT fund shows its cards.

31 March 2020

1 reference

Ivermectin, 'wonder drug' from Japan: the human use perspective

31 March 2020

1 reference

Advances in drug discovery and biochemical studies

31 March 2020

1 reference

The life and times of ivermectin - a success story

31 March 2020

1 reference

Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite

31 March 2020

1 reference

A historical perspective on the discovery of statins

31 March 2020

1 reference

Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors

31 March 2020

1 reference

New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays

31 March 2020

1 reference

A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening

31 March 2020

1 reference

Chemistry: Chemical con artists foil drug discovery

31 March 2020

1 reference

Challenges in antimalarial drug discovery

31 March 2020

1 reference

A male and female gametocyte functional viability assay to identify biologically relevant malaria transmission-blocking drugs

31 March 2020

1 reference

Cellular and genetic mechanisms underlying susceptibility of animal models to tuberculosis infection.

31 March 2020

1 reference

Role of hERG potassium channel assays in drug development

31 March 2020

1 reference

Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26435527

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

History of the discovery of cyclosporin and of its early pharmacological development.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26435527

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

In Vitro Model of Hypoxically Induced Nonreplicating Persistence of Mycobacterium tuberculosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26435527

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRD4683

1 reference

Dimensions Publication ID

4 September 2017

1010026640

0 references

1 reference